Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Grabar Law Office is actively investigating claims on behalf of MacroGenics, Inc. (NASDAQ: MGNX) shareholders. If you have ...
MacroGenics, Inc. (NASDAQ:MGNX – Free Report) – Investment analysts at B. Riley issued their FY2024 EPS estimates for shares ...
Hosted on MSN6d
JMP Securities Downgrades MacroGenics (MGNX)Fintel reports that on November 7, 2024, JMP Securities downgraded their outlook for MacroGenics (NasdaqGS:MGNX) from Market ...
JMP has downgraded MacroGenics (NASDAQ:MGNX) to market perform, calling the shares fairly valued. Noting that the company’s pipeline was in a “holding pattern,” JMP said it was downgrading the stock ...
Maryland-based MacroGenics, a biopharma focused on discovering, developing, manufacturing and commercializing innovative ...
On Wednesday, MacroGenics Inc (MGNX) stock saw a modest uptick, ending the day at $4.19 which represents a slight increase of $0.42 or 11.14% from the prior close of $3.77. The stock opened at $4.59 ...
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MGNX), a biopharmaceutical company focused on developing, ...
MacroGenics has pumped the brakes on vobramitamab duocarmazine (vobra duo), pausing investment in additional opportunities ...
TD Cowen analyst Tara Bancroft has maintained their neutral stance on MGNX stock, giving a Hold rating on October 23. Tara Bancroft’s ...
MacroGenics (NASDAQ: MGNX) Q3 2024 Earnings Call Nov 05, 2024, 4:30 p.m. ET ...
A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback